Home » Stocks » CCXI

ChemoCentryx, Inc. (CCXI)

Stock Price: $62.02 USD -1.37 (-2.16%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
Market Cap 4.27B
Revenue (ttm) 70.58M
Net Income (ttm) -41.01M
Shares Out 68.92M
EPS (ttm) -0.65
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $62.02
Previous Close $63.39
Change ($) -1.37
Change (%) -2.16%
Day's Open 63.03
Day's Range 60.79 - 63.88
Day's Volume 362,488
52-Week Range 32.73 - 65.16

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 1 week ago

MOUNTAIN VIEW, Calif., Jan. 06, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present a...

Zacks Investment Research - 3 weeks ago

ChemoCentryx (CCXI) and Vifor Fresenius Medical Care Renal Pharma report positive top-line data from the study evaluating avacopan for the treatment of C3 Glomerulopathy.

GlobeNewsWire - 3 weeks ago

MOUNTAIN VIEW, Calif. and ST. GALLEN, Switzerland, Dec. 21, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced topline data from...

Zacks Investment Research - 1 month ago

ChemoCentryx (CCXI) reported earnings 30 days ago. What's next for the stock?

GlobeNewsWire - 1 month ago

MOUNTAIN VIEW, Calif., Nov. 19, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present a...

Zacks Investment Research - 2 months ago

ChemoCentryx (CCXI) reports a wider-than-expected Q3 loss and misses sales estimates in the third quarter of 2020.

Seeking Alpha - 2 months ago

ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 2 months ago

ChemoCentryx (CCXI) delivered earnings and revenue surprises of -25.00% and -60.46%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the st...

Benzinga - 2 months ago

Shares of ChemoCentryx (NASDAQ:CCXI) fell 8.59% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were down 59.09% year over year to ($0.35), ...

GlobeNewsWire - 2 months ago

-- New Drug Application (NDA ) accepted for review by U.S. Food and Drug Administration (FDA) for avacopan in ANCA -associated vasculitis with PDUFA goal date of July 7, 2021 -- -- Marketing A...

GlobeNewsWire - 2 months ago

-- Study Showed T reatment with Avacopan A chieved Statistical Superiority in Sustaining Remission at 52 Weeks and G reater I mprovement in R enal F unction C ompared to the Prednisone Group -...

GlobeNewsWire - 2 months ago

ST. GALLEN, Switzerland and MOUNTAIN VIEW, Calif., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma (VFMCRP) Ltd. and ChemoCentryx, Inc., today announced that the Eu...

GlobeNewsWire - 2 months ago

MOUNTAIN VIEW, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2020 financial results will be released after mark...

GlobeNewsWire - 2 months ago

-- Avacopan demonstrates statistically significant dose-dependent improvement in HiSCR (Hidradenitis Suppurativa Clinical Response) vs. placebo in pre-specified Hurley Stage III (severe HS) pa...

Zacks Investment Research - 2 months ago

ChemoCentryx (CCXI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CNBC Television - 2 months ago

Final Trades: AT&T, Jumia Technologies, Chemocentryx, General Motors

The “Halftime Report” traders give their top picks to watch for the second half.

Other stocks mentioned: GM, JMIA, T
InvestorPlace - 3 months ago

The pandemic has raised awareness about the value of biotech across the world. In turn, these biotech stocks will benefit down the road.

Other stocks mentioned: ADAP, KOD, MCRB, MYOV, NVAX, SRNE
Zacks Investment Research - 3 months ago

The FDA accepts ChemoCentryx's (CCXI) NDA for avacopan, for the treatment of ANCA-associated vasculitis.

GlobeNewsWire - 3 months ago

-- FDA sets PDUFA goal date of July 7, 2021 -- MOUNTAIN VIEW, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the U.S. Food and Drug Admin...

GlobeNewsWire - 4 months ago

MOUNTAIN VIEW, Calif., Sept. 08, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will presen...

Seeking Alpha - 5 months ago

ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 5 months ago

ChemoCentryx (CCXI) delivered earnings and revenue surprises of 185.29% and 494.95%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

GlobeNewsWire - 5 months ago

-- U.S. New Drug Application (NDA) submitted for avacopan in ANCA-associated vasculitis -- -- Balance sheet bolstered with $325.7 million in net proceeds from June follow-on offering; total ...

GlobeNewsWire - 5 months ago

MOUNTAIN VIEW, Calif., Aug. 03, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's second quarter 2020 financial results will be released after m...

Zacks Investment Research - 5 months ago

ChemoCentryx (CCXI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

GlobeNewsWire - 6 months ago

MOUNTAIN VIEW, Calif., July 09, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) today confirmed that the Company has submitted a New Drug Application (NDA) to the U.S. Food and D...

Zacks Investment Research - 6 months ago

Investors need to pay close attention to ChemoCentryx (CCXI) stock based on the movements in the options market lately.

GlobeNewsWire - 6 months ago

-- Study to be presented at American Association for Cancer Research (AACR) meeting showed the Company’s orally administered small molecule checkpoint inhibitors led to marked inhibition of PD...

GlobeNewsWire - 7 months ago

MOUNTAIN VIEW, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq: CCXI) announced today the completion of its follow-on offering of 5,200,000 shares of its common stock. C...

GlobeNewsWire - 7 months ago

MOUNTAIN VIEW, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has priced an underwritten public offering of 5,200,000 shares of its common...

GlobeNewsWire - 7 months ago

MOUNTAIN VIEW, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has commenced an underwritten public offering of its common stock.  In conne...

Seeking Alpha - 7 months ago

ChemoCentryx: Avacopan's Attractive Value Proposition

GlobeNewsWire - 7 months ago

MOUNTAIN VIEW, Calif. and ST GALLEN, CH, May 18, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced topline da...

Seeking Alpha - 8 months ago

ChemoCentryx, Inc. (CCXI) CEO Dr.

Zacks Investment Research - 8 months ago

ChemoCentryx (CCXI) delivered earnings and revenue surprises of -16.67% and -32.49%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 8 months ago

Does ChemoCentryx (CCXI) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 9 months ago

ChemoCentryx (CCXI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

GuruFocus - 9 months ago

According to the GuruFocus All-in-One Screener, a Premium feature, the following guru-owned stocks have outperformed the S&P 500 Index over the past 12 months as of March 31.

Other stocks mentioned: AXSM, DXCM, EIDX, ENPH
InvestorPlace - 9 months ago

Wall Street pros recommend making an investment decision based on multiple factors rather than just a single metric like fundamentals.

Other stocks mentioned: ARCT, AUPH, KDMN, NVAX, NVRO, TMO
Zacks Investment Research - 9 months ago

ChemoCentryx (CCXI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

Seeking Alpha - 10 months ago

ChemoCentryx, Inc. (CCXI) CEO Thomas Schall on Q4 2019 Results - Earnings Call Transcript

Zacks Investment Research - 10 months ago

ChemoCentryx (CCXI) delivered earnings and revenue surprises of 3.70% and 6.70%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 10 months ago

ChemoCentryx (CCXI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 11 months ago

ChemoCentryx: An Intriguing Rare Disease Player In 2020

The Motley Fool - 1 year ago

Positive trial results are always a good thing, but is this newly hyped stock worth it?

Seeking Alpha - 1 year ago

ChemoCentryx Brings Hope To Vasculitis Patients, Steroid Therapy Can Play A Smaller Role

Zacks Investment Research - 1 year ago

ChemoCentryx (CCXI) announces positive data pivotal study evaluating its lead candidate, avacopan, in patients with ANCA vasculitis, a rare disease affecting small blood vessels.

The Motley Fool - 1 year ago

The company unveiled positive data for the most advanced drug in its pipeline.

The Motley Fool - 1 year ago

Find out how three stocks in very different sectors all posted solid gains.

Other stocks mentioned: DKS, NTNX
GlobeNewsWire - 1 year ago

-- Achieved both primary endpoints of clinical remission at weeks 26 and 52 with statistical superiority of avacopan over standard of care (SOC) at 52 weeks --   -- Significantly reduced gl...

About CCXI

ChemoCentryx, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe h... [Read more...]

Industry
Biotechnology
IPO Date
Feb 8, 2012
CEO
Thomas Schall
Employees
82
Stock Exchange
NASDAQ
Ticker Symbol
CCXI
Full Company Profile

Financial Performance

In 2019, ChemoCentryx's revenue was $36.13 million, a decrease of -15.74% compared to the previous year's $42.88 million. Losses were -$55.49 million, 46.2% more than in 2018.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for ChemoCentryx stock is "Buy." The 12-month stock price forecast is 80.63, which is an increase of 30.01% from the latest price.

Price Target
$80.63
(30.01% upside)
Analyst Consensus: Buy